EP3418304A4 - Reconnaissance de protéine de type mucine de type membranaire et son application clinique - Google Patents

Reconnaissance de protéine de type mucine de type membranaire et son application clinique Download PDF

Info

Publication number
EP3418304A4
EP3418304A4 EP17752868.4A EP17752868A EP3418304A4 EP 3418304 A4 EP3418304 A4 EP 3418304A4 EP 17752868 A EP17752868 A EP 17752868A EP 3418304 A4 EP3418304 A4 EP 3418304A4
Authority
EP
European Patent Office
Prior art keywords
type
mucinary
recognition
clinical application
membrane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP17752868.4A
Other languages
German (de)
English (en)
Other versions
EP3418304A1 (fr
EP3418304B1 (fr
Inventor
Shoutaro Tsuji
Taihei KAGEYAMA
Kota WASHIMI
Makiko Tsuji
Rieko MATSUURA
Mitsuyo YOSHIHARA
Kohzoh Imai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tokyo NUC
Kanagawa Prefectural Hospital Organization
Original Assignee
University of Tokyo NUC
Kanagawa Prefectural Hospital Organization
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tokyo NUC, Kanagawa Prefectural Hospital Organization filed Critical University of Tokyo NUC
Priority to PL17752868T priority Critical patent/PL3418304T3/pl
Publication of EP3418304A1 publication Critical patent/EP3418304A1/fr
Publication of EP3418304A4 publication Critical patent/EP3418304A4/fr
Application granted granted Critical
Publication of EP3418304B1 publication Critical patent/EP3418304B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
EP17752868.4A 2016-02-15 2017-01-16 Reconnaissance de protéine de type mucine de type membranaire et son application clinique Active EP3418304B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL17752868T PL3418304T3 (pl) 2016-02-15 2017-01-16 Rozpoznawanie białka typu błonowego podobnego do mucyny i jego zastosowanie kliniczne

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016025689 2016-02-15
PCT/JP2017/001250 WO2017141604A1 (fr) 2016-02-15 2017-01-16 Reconnaissance de protéine de type mucine de type membranaire et son application clinique

Publications (3)

Publication Number Publication Date
EP3418304A1 EP3418304A1 (fr) 2018-12-26
EP3418304A4 true EP3418304A4 (fr) 2019-08-07
EP3418304B1 EP3418304B1 (fr) 2021-08-04

Family

ID=59624936

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17752868.4A Active EP3418304B1 (fr) 2016-02-15 2017-01-16 Reconnaissance de protéine de type mucine de type membranaire et son application clinique

Country Status (8)

Country Link
US (1) US12123876B2 (fr)
EP (1) EP3418304B1 (fr)
JP (2) JP6859498B2 (fr)
CN (1) CN108699159B (fr)
DK (1) DK3418304T3 (fr)
ES (1) ES2888024T3 (fr)
PL (1) PL3418304T3 (fr)
WO (1) WO2017141604A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108699159B (zh) 2016-02-15 2022-07-29 地方独立行政法人神奈川县立病院机构 膜型粘蛋白样蛋白质的识别及其医疗应用
CN116615250A (zh) * 2020-11-12 2023-08-18 第一三共株式会社 通过施用抗b7-h3抗体-药物缀合物的间皮瘤治疗
JPWO2023277113A1 (fr) * 2021-06-30 2023-01-05
WO2023277144A1 (fr) * 2021-06-30 2023-01-05 日本メジフィジックス株式会社 Anticorps humanisé capable de se lier à la protéine heg1 et complexe dudit anticorps et d'une espèce nucléaire radioactive
EP4397320A1 (fr) 2021-08-31 2024-07-10 Nihon Medi-Physics Co., Ltd. Complexe radioactif d'anticorps déglycosylé et produit pharmaceutique radioactif
CN120813388A (zh) 2023-03-02 2025-10-17 日本医事物理股份有限公司 放射性金属标记抗体、放射性药物及化合物
CN118852420B (zh) * 2024-08-16 2025-11-11 东北农业大学 一种猪δ冠状病毒中和性单克隆抗体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009068204A1 (fr) * 2007-11-26 2009-06-04 Bayer Schering Pharma Aktiengesellschaft Anticorps anti-mésothéline et leurs utilisations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004528828A (ja) 2001-02-07 2004-09-24 ザ ジェネラル ホスピタル コーポレーション 心疾患の診断および治療の方法
EP2287202A1 (fr) * 2009-08-07 2011-02-23 Dublin City University Molécules d'anticorps anti-acide sialique
US9588121B2 (en) 2009-11-06 2017-03-07 Go Therapeutics, Inc. Method for early detection of cancer
WO2015121454A1 (fr) * 2014-02-14 2015-08-20 Cellectis Cellules destinées à l'immunothérapie modifiées pour cibler un antigène présent à la fois sur les cellules immunitaires et les cellules pathologiques
US20180057553A1 (en) 2015-03-05 2018-03-01 The University Of Tokyo Conjugate and use thereof
CN108699159B (zh) 2016-02-15 2022-07-29 地方独立行政法人神奈川县立病院机构 膜型粘蛋白样蛋白质的识别及其医疗应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009068204A1 (fr) * 2007-11-26 2009-06-04 Bayer Schering Pharma Aktiengesellschaft Anticorps anti-mésothéline et leurs utilisations

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ANNEMARIE ZIEGLER ET AL: "Proteomic surfaceome analysis of mesothelioma", LUNG CANCER, ELSEVIER, AMSTERDAM, NL, vol. 75, no. 2, 13 July 2011 (2011-07-13), pages 189 - 196, XP028435246, ISSN: 0169-5002, [retrieved on 20110720], DOI: 10.1016/J.LUNGCAN.2011.07.009 *
CHANG K ET AL: "MOLECULAR CLONING OF MESOTHELIN, A DIFFERENTIATION ANTIGEN PRESENT ON MESOTHELIUM, MESOTHELIOMAS, AND OVARIAN CANCERS", PNAS, NATIONAL ACADEMY OF SCIENCES, US, vol. 93, 9 January 1996 (1996-01-09), pages 136 - 140, XP002038954, ISSN: 0027-8424, DOI: 10.1073/PNAS.93.1.136 *
D. ROULOIS ET AL: "Recognition of pleural mesothelioma by mucin-1(950-958)/human leukocyte antigen A*0201-specific CD8+ T-cells", EUROPEAN RESPIRATORY JOURNAL, vol. 38, no. 5, 3 May 2011 (2011-05-03), GB, pages 1117 - 1126, XP055600692, ISSN: 0903-1936, DOI: 10.1183/09031936.00160210 *
HASSAN ET AL: "Mesothelin targeted cancer immunotherapy", EUROPEAN JOURNAL OF CANCER, ELSEVIER, AMSTERDAM, NL, vol. 44, no. 1, 22 October 2007 (2007-10-22), pages 46 - 53, XP022392314, ISSN: 0959-8049, DOI: 10.1016/J.EJCA.2007.08.028 *
J CREANEY ET AL: "Overexpression and altered glycosylation of MUC1 in malignant mesothelioma", BRITISH JOURNAL OF CANCER, vol. 98, no. 9, 29 April 2008 (2008-04-29), GB, pages 1562 - 1569, XP055600694, ISSN: 0007-0920, DOI: 10.1038/sj.bjc.6604340 *
RIEKO MATSUURA ET AL: "Identification of mesothelioma-specific sialylated epitope recognized with monoclonal antibody SKM9-2 in a mucin-like membrane protein HEG1", SCIENTIFIC REPORTS, vol. 8, no. 1, 24 September 2018 (2018-09-24), XP055600681, DOI: 10.1038/s41598-018-32534-8 *
See also references of WO2017141604A1 *
SHOUTARO TSUJI ET AL: "HEG1 is a novel mucin-like membrane protein that serves as a diagnostic and therapeutic target for malignant mesothelioma", SCIENTIFIC REPORTS, vol. 7, no. 1, 31 March 2017 (2017-03-31), XP055600682, DOI: 10.1038/srep45768 *

Also Published As

Publication number Publication date
CN108699159A (zh) 2018-10-23
US12123876B2 (en) 2024-10-22
US20190071517A1 (en) 2019-03-07
PL3418304T3 (pl) 2021-12-20
JP2020196730A (ja) 2020-12-10
EP3418304A1 (fr) 2018-12-26
ES2888024T3 (es) 2021-12-30
JPWO2017141604A1 (ja) 2019-03-07
JP6859498B2 (ja) 2021-04-14
WO2017141604A1 (fr) 2017-08-24
DK3418304T3 (da) 2021-09-20
CN108699159B (zh) 2022-07-29
EP3418304B1 (fr) 2021-08-04

Similar Documents

Publication Publication Date Title
EP3418304A4 (fr) Reconnaissance de protéine de type mucine de type membranaire et son application clinique
IL268781A (en) Cd80 variant immunomodulatory proteins and uses thereof
LT3515490T (lt) Antikūnai prieš signalą reguliuojantį baltymą alfa, ir naudojimo būdai
EP3542284A4 (fr) Identification et interprétation d'images médicales
IL262240A (en) Anti-human vista antibodies and use thereof
IL262092A (en) Humanized anti-pacap antibodies and uses thereof
IL268704B (en) Formulations of human anti-rankl antibodies, and methods of using the same
IL268780A (en) Pd-l1 variant immunomodulatory proteins and uses thereof
PT3694529T (pt) Proteínas triespecíficas e métodos de utilização
PL3484916T3 (pl) Przeciwciała swoiste wobec hiperfosforylowanego białka tau i sposoby ich zastosowania
IL281579B (en) Compositions and methods for detecting a biological contaminant
EP3313863A4 (fr) Constructions de fusion de degron et procédés de régulation de la production de protéine
EP3479377A4 (fr) Reconnaissance de la parole
IL247459B (en) Anti human interleukin-1 receptor accessory protein (il1 rap) antibodies and uses thereof
EP3634976A4 (fr) Détermination d'interactions petite molécule-protéine et protéine-protéine
PL3565828T3 (pl) Białko fuzyjne SIRP1 ALFA-41BBL i sposoby jego zastosowania
EP3526732A4 (fr) Réduction de la complexité de reconnaissance d'objet à interaction humaine
LT3525583T (lt) Anti-c1s antikūnai ir jų naudojimo būdai
IL254670A0 (en) Humanized anti-c1s antibodies and methods of use thereof
EP3432733A4 (fr) Concentré de protéine de maïs et ses procédés de fabrication
EP3494193A4 (fr) Réticulation de membranes de type polybenzimidazolium et polyimidazolium stables à l'hydroxyde et ionomères
EP3290514A4 (fr) Application de la protéine pi4kiii et du complexe de protéines membranaires associées dans le traitement de la maladie d'alzheimer
IL261740A (en) Compositions and methods for treatment of type vii collagen deficiencies
EP3722305A4 (fr) Protéine de fusion hm-3 et son utilisation
EP3538541A4 (fr) Préparation et utilisation de ginsénosides et de peptides de type ginsénoside

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180906

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190709

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/09 20060101ALI20190703BHEP

Ipc: G01N 33/574 20060101ALI20190703BHEP

Ipc: C07K 14/705 20060101ALI20190703BHEP

Ipc: A61K 49/00 20060101ALI20190703BHEP

Ipc: C07K 16/30 20060101AFI20190703BHEP

Ipc: C12N 15/62 20060101ALI20190703BHEP

Ipc: A61P 35/00 20060101ALI20190703BHEP

Ipc: A61K 39/395 20060101ALI20190703BHEP

Ipc: A61K 49/16 20060101ALI20190703BHEP

Ipc: G01N 33/68 20060101ALI20190703BHEP

Ipc: C07K 16/46 20060101ALI20190703BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200610

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20210215

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE UNIVERSITY OF TOKYO

Owner name: KANAGAWA PREFECTURAL HOSPITAL ORGANIZATION

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1416922

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210815

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602017043398

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: FI

Ref legal event code: FGE

RAP4 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: THE UNIVERSITY OF TOKYO

Owner name: KANAGAWA PREFECTURAL HOSPITAL ORGANIZATION

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20210915

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20210804

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2888024

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20211230

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210804

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210804

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210804

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211104

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211206

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210804

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211105

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602017043398

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210804

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210804

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210804

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210804

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210804

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20220506

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210804

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210804

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 1416922

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210804

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230512

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20170116

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210804

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210804

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210804

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210804

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20251127

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FI

Payment date: 20251230

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20251128

Year of fee payment: 10

Ref country code: NL

Payment date: 20251215

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20251223

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20251210

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20251209

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20251212

Year of fee payment: 10

REG Reference to a national code

Ref country code: CH

Ref legal event code: U11

Free format text: ST27 STATUS EVENT CODE: U-0-0-U10-U11 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20260201

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20260116

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20260203

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NO

Payment date: 20260109

Year of fee payment: 10

Ref country code: DE

Payment date: 20251203

Year of fee payment: 10

Ref country code: DK

Payment date: 20260113

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20251230

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20251219

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CZ

Payment date: 20260109

Year of fee payment: 10

Ref country code: CH

Payment date: 20260201

Year of fee payment: 10